Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, November 22 '25)

Image
By G.M.

 


    Ann Intern Med

  1. QASEEM A, Wilt TJ, Harrod CS, Obley AJ, et al
    Influenza Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
    Ann Intern Med. 2025 Nov 18. doi: 10.7326/ANNALS-25-04056.
    PubMed         Abstract available


  2. Web Exclusive. Annals Video Summary - Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
    Ann Intern Med. 2025 Nov 18:e2504658VS. doi: 10.7326/ANNALS-25-04658.
    PubMed        

  3. DOBRESCU AI, Sharifan A, Sommer I, Neubauer-Bruckner CIA, et al
    Comparative Effectiveness and Harm of Seasonal Influenza Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
    Ann Intern Med. 2025 Nov 18. doi: 10.7326/ANNALS-25-04028.
    PubMed         Abstract available


    BMC Pediatr

  4. LIN YF, Fang SY, Huang SC, Wu ET, et al
    Severe myocardium suppression in two congenital heart disease patients after remdesivir use - a case report.
    BMC Pediatr. 2025;25:934.
    PubMed         Abstract available


    J Gen Virol

  5. OHRNBERGER S, Meyer Zu Natrup C, Clever S, Schunemann LM, et al
    Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate.
    J Gen Virol. 2025;106:002180.
    PubMed         Abstract available

  6. ENTRIKEN CG, Bruce KL, Coyne BM, Kruyer SH, et al
    Improved efficacy of an influenza DNA vaccine through high-density microarray patch delivery.
    J Gen Virol. 2025;106:002179.
    PubMed         Abstract available


    J Infect

  7. HAN S, Liu Y, Xing B, Yang Y, et al
    Association of Glucagon-Like Peptide-1 Receptor Agonist Use with Risk of Infections: A Systematic Review and Meta-analysis.
    J Infect. 2025 Oct 29:106645. doi: 10.1016/j.jinf.2025.106645.
    PubMed         Abstract available

  8. BORROW R, Caugant DA, Clark SA, Dinleyici EC, et al
    Current global trends in meningococcal disease control, risk groups and vaccination: Consensus of the Global Meningococcal Initiative.
    J Infect. 2025 Oct 17:106635. doi: 10.1016/j.jinf.2025.106635.
    PubMed         Abstract available


    J Infect Dis

  9. TENFORDE MW, Garg S, Chung J, Adams K, et al
    The role of antiviral treatment of influenza in reducing hospitalizations and other severe outcomes: A need for more evidence.
    J Infect Dis. 2025 Nov 14:jiaf573. doi: 10.1093.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  10. OLMSTED KE, Ramsey-Omonua T, Thomas ES, Lee JT, et al
    Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:589-591.
    PubMed         Abstract available


    N Engl J Med

  11. FITZ-PATRICK D, McVinnie DS, Jackson LA, Crowther G, et al
    Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.
    N Engl J Med. 2025;393:2001-2011.
    PubMed         Abstract available

  12. EL SAHLY HM, Atmar RL
    An Early Look at mRNA Vaccines to Prevent Influenza.
    N Engl J Med. 2025;393:2048-2050.
    PubMed        


    PLoS Comput Biol

  13. PARKER NT, Hong V, Davis GS, Pomichowski M, et al
    Clinical progression parameters associated with SARS-CoV-2, influenza, and respiratory syncytial virus infections in a large US integrated healthcare population.
    PLoS Comput Biol. 2025;21:e1013723.
    PubMed         Abstract available

  14. BILLINGS WZ, Ge Y, Skarlupka AL, Miller SL, et al
    Different antigenic distance metrics generate similar predictions of influenza vaccine response breadth despite moderate correlation.
    PLoS Comput Biol. 2025;21:e1013720.
    PubMed         Abstract available


    PLoS One

  15. HARRIS R, Kolahdooz F, Omidimorad A, Wagg A, et al
    Communication access, public health information sources, and language preference during the COVID-19 pandemic in Indigenous communities in Northwest Territories, Canada.
    PLoS One. 2025;20:e0330394.
    PubMed         Abstract available

  16. NALEWAJ M, Sliwiak J, Zielinska K, Zmora P, et al
    The interaction of RNA G-quadruplexes from the influenza A virus vRNA with TMPyP4 and BRACO-19 ligands.
    PLoS One. 2025;20:e0335975.
    PubMed         Abstract available

  17. ADDAE EA, Adjei M, Anaduaka US, Wuollah-Dire DK, et al
    A mediation model explaining the impact of fear of COVID-19 and COVID-19- induced changes in multiple life domains on adolescents' subjective well-being in sub-Saharan Africa.
    PLoS One. 2025;20:e0337188.
    PubMed         Abstract available

  18. LEE L, Diallo F, Shiman LJ
    The intersection of food insecurity and child health: Implications for policy and practice in the Bronx.
    PLoS One. 2025;20:e0335355.
    PubMed         Abstract available

  19. DZOMBA A, Mataboge P, Kelly NK, Oladimeji KE, et al
    Concern for severe COVID-19 disease during the initial two years of pandemic in a rural South African community: A population-based study.
    PLoS One. 2025;20:e0319720.
    PubMed         Abstract available

  20. DAI D, Gois PF, Wainstein M, Ghadimi M, et al
    Omicron surge impact on acute kidney injury in ICU patients: A study using the ISARIC COVID-19 database.
    PLoS One. 2025;20:e0336843.
    PubMed         Abstract available

  21. YUAN M, Liang M, Xu J, He D, et al
    Clinical characteristics and predictive models for hospitalized patients with COVID-19 combined with bacterial pneumonia.
    PLoS One. 2025;20:e0336668.
    PubMed         Abstract available

  22. IBRAHIM N, Jones S, Rich K, Alvarez L, et al
    Evaluation of a "one-stop shop" for integrated harm reduction and primary care for people who inject drugs.
    PLoS One. 2025;20:e0337528.
    PubMed         Abstract available

  23. HOSP JA, Schroter N, Reisert M, Frase S, et al
    Fatigue in Post-COVID-Condition is accompanied by hypoperfusion of right-occipital areas.
    PLoS One. 2025;20:e0335038.
    PubMed         Abstract available

  24. JI CX, Sorouri M, Abdollahi M, Paknejad O, et al
    Can physiological network mapping reveal pathophysiological insights into emerging diseases? Lessons from COVID-19.
    PLoS One. 2025;20:e0337333.
    PubMed         Abstract available

  25. DATKHILE G, Kachare PH, Sangle SB, Al-Shourbaji I, et al
    Speech-based respiratory diagnostics: A study on COVID-19 detection with machine learning.
    PLoS One. 2025;20:e0332146.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  26. HOLEC PV, Breuckman KC, Leddy O, White FM, et al
    High-throughput screening for class I peptide MHC binding via yeast surface display.
    Proc Natl Acad Sci U S A. 2025;122:e2514741122.
    PubMed         Abstract available


    Vaccine

  27. WILLIAMS LR, Voysey M, Pollard AJ, Grassly NC, et al
    A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.
    Vaccine. 2025;67:127856.
    PubMed         Abstract available

  28. DONAHUE JG, Cocoros NM, Kieke BA, Hanson KE, et al
    Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink.
    Vaccine. 2025;67:127873.
    PubMed         Abstract available

  29. RUSSO L, Farina S, Macri RA, Pentecost WA, et al
    State-level progress and setbacks in influenza vaccination among adults >/=65: A fifteen-season analysis from 2009/10 to 2023/24.
    Vaccine. 2025;69:127983.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »